Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

WideCells unveils fund-raising details

The group had flagged its plans to raise funds, without which it was at risk of not being able to continue trading as a going concern
Pound notes
Private investors can buy newly issued shares via the Teathers app

Healthcare services company WideCells Group PLC (LON:WDC) is planning to raise at least £1.47mln through a share placing at 3p a pop.

The company said in a statement that it has received commitments to take just over 49mln new shares.

READ: WideCells Group delays publication of 2017 results as fund-raising talks continue

Additionally, as part of the placing, the group intends to raise up to a further £450,000 through a book-build conducted through the Teathers app, which is an app designed to give private investors the chance to participate in fund-raising exercises that are normally restricted to institutional investors.

WideCells said the funds raised would be used to expand the group’s core end-to-end stem cell services as it looks to ramp-up its revenue, largely through driving sales of its global stem cell insurance plan, CellPlan, and its stem cell storage services.

Shares in WideCells are currently suspended, pending publication of its annual results.

View full WDC profile View Profile

WideCells Group Timeline

Related Articles

June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
April 12 2018
Mission is to make stem cell treatments accessible and affordable to as many people as possible
July 30 2018
Life science generally is developing at an incredible speed, says Joe Anderson

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use